PUBLISHER: The Business Research Company | PRODUCT CODE: 1942590
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942590
A complete blood count (CBC) device is a medical tool used to conduct a complete blood count, a common laboratory test that measures the levels and characteristics of different blood components. This device automates the blood analysis process, providing accurate and quick results that help healthcare professionals make informed diagnostic and treatment decisions.
The main categories of complete blood count devices include automated blood count analyzers, manual blood count analyzers, point-of-care testing devices, and hematology analyzers. Automated blood count analyzers are sophisticated instruments that utilize various technologies to quickly and precisely count and classify blood cells, improving efficiency and minimizing manual errors in clinical laboratories. These devices perform tests such as white blood cell (WBC) count, WBC differential count, red blood cell (RBC) count, hematocrit (HCT), hemoglobin (HGB), platelet count, mean platelet volume (MPV), mean corpuscular hemoglobin (MCH), and others. They employ technologies like impedance, laser-based methods, flow cytometry, and microscopy. Distribution occurs through channels such as direct sales, online platforms, third-party distributors, and retail pharmacies, with end-users including hospitals, diagnostic labs, research centers, and more.
Tariffs are influencing the complete blood count device market by increasing costs of imported sensors, microfluidic components, lasers, reagents, and electronic control units used in automated and point-of-care analyzers. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported high-precision components, while Asia-Pacific faces cost pressures on device exports. These tariffs are raising procurement costs and slowing equipment replacement cycles. At the same time, they are supporting domestic manufacturing, regional supply chain localization, and increased innovation in cost-efficient diagnostic device design.
The complete blood count device market research report is one of a series of new reports from The Business Research Company that provides complete blood count device market statistics, including complete blood count device industry global market size, regional shares, competitors with a complete blood count device market share, detailed complete blood count device market segments, market trends and opportunities, and any further data you may need to thrive in the complete blood count device industry. This complete blood count device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The complete blood count device market size has grown strongly in recent years. It will grow from $4.33 billion in 2025 to $4.58 billion in 2026 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to expansion of clinical diagnostic testing volumes, increased hospital laboratory automation, growing burden of chronic diseases, availability of standardized blood testing protocols, rising demand for routine health screenings.
The complete blood count device market size is expected to see strong growth in the next few years. It will grow to $5.76 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing adoption of decentralized diagnostics, rising investments in smart laboratory infrastructure, growing demand for rapid diagnostic results, expansion of preventive healthcare testing, continuous advancements in hematology technology. Major trends in the forecast period include increasing adoption of automated hematology analyzers, rising demand for point-of-care cbc devices, growing integration of ai-based diagnostics, expansion of high-throughput laboratory systems, enhanced focus on diagnostic accuracy and speed.
The growing prevalence of blood disorders is expected to drive the growth of the complete blood count (CBC) device market in the coming years. Blood disorders are conditions that impair the production, function, or structure of blood cells, leading to compromised blood function. The rise in these disorders is associated with the increasing incidence of lifestyle-related diseases, where poor diet, physical inactivity, and stress contribute to conditions such as anemia and clotting abnormalities. Complete blood count devices assist in diagnosing blood disorders by analyzing key blood components and detecting abnormalities, enabling healthcare professionals to identify clotting issues and provide timely, precise treatment. For example, in May 2024, the Canadian Cancer Society reported that 4,100 individuals in Canada were diagnosed with multiple myeloma, a type of blood cancer, and 1,750 individuals died from the disease. Consequently, the increasing prevalence of blood disorders is propelling the expansion of the CBC device market.
Companies in the CBC device market are developing advanced products such as compact hematology analyzers to deliver faster, more accurate, and cost-effective solutions for point-of-care testing. These portable, user-friendly devices provide complete blood count results quickly and with minimal sample volume, enhancing diagnostic accuracy, efficiency, and ease of use. For instance, in June 2024, HORIBA, a Japan-based analytical and measurement technology company, launched the Yumizen H550E and H500E hematology analyzers. These compact analyzers integrate erythrocyte sedimentation rate (ESR) testing with CBC and 5-part differential (DIFF) analysis, using HORIBA's patented CoRA (correlated rouleaux analysis) technology to provide comprehensive results from whole blood samples in just 60 seconds.
In February 2024, Sysmex Corporation, a Japan-based hematology analyzer manufacturer, partnered with CellaVision AB to advance hematology through AI-driven digital cell morphology. The collaboration aims to improve efficiency, precision, and standardization in hematology testing by combining Sysmex's expertise with CellaVision's imaging technologies, enabling more accurate diagnoses and better clinical outcomes. CellaVision AB is a Sweden-based provider of digital hematology microscopy solutions.
Major companies operating in the complete blood count device market are Abbott Laboratories, Siemens Healthineers, Mindray Medical International Limited, Beckman Coulter Inc., Sysmex Corporation, Horiba Ltd., Nihon Kohden Corporation, Agappe Diagnostics Ltd., Trivitron Healthcare Pvt. Ltd., HemoCue AB, EKF Diagnostics Holdings plc, Erba Mannheim, Boule Diagnostics AB, Biosystems S.A., Diatron MI Zrt., Labtron Equipment Ltd., Microlab Instruments Co. Pvt. Ltd., URIT Medical Electronic Co. Ltd., Roche Diagnostics, Ortho Clinical Diagnostics, BioSystems Diagnostics Pvt. Ltd., Drew Scientific (subsidiary of EKF), Analyticon Biotechnologies GmbH, Rayto Life and Analytical Sciences Co. Ltd.
North America was the largest region in the complete blood count device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complete blood count device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the complete blood count device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The complete blood count (CBC) device market consists of sales of automated hematology analyzers, point-of-care CBC devices, reagents and consumables. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Complete Blood Count Device Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses complete blood count device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for complete blood count device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The complete blood count device market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.